APA (7th ed.) Citation

N, V., CW, H., SC, S., KF, C., E, O., JS, A., & KL, S. (2025). Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA-Labeled Dosing Frequency of RHB-105 Low-Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication. Journal of clinical pharmacology, 65(6), 779. https://doi.org/10.1002/jcph.6178

Chicago Style (17th ed.) Citation

N, Vakil, Howden CW, Shah SC, Chen KF, Offman E, Almenoff JS, and Sheldon KL. "Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA-Labeled Dosing Frequency of RHB-105 Low-Dose Rifabutin Triple Therapy for Helicobacter Pylori Eradication." Journal of Clinical Pharmacology 65, no. 6 (2025): 779. https://doi.org/10.1002/jcph.6178.

MLA (9th ed.) Citation

N, Vakil, et al. "Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA-Labeled Dosing Frequency of RHB-105 Low-Dose Rifabutin Triple Therapy for Helicobacter Pylori Eradication." Journal of Clinical Pharmacology, vol. 65, no. 6, 2025, p. 779, https://doi.org/10.1002/jcph.6178.